News | November 22, 2022
Natural Biogenex completes its maiden fund-raise of Rs 18.75 Cr
The proceeds from this fund-raise will be deployed in financing the project requirements of the API business
The proceeds from this fund-raise will be deployed in financing the project requirements of the API business
The Bulk Drug Parks to be developed under the scheme will provide common infrastructure facilities at one place thereby creating a robust ecosystem for the bulk drug manufacturing in the country and also reducing manufacturing cost significantly
India exported about Rs 33,321 crore and imported Rs 35,249 crore worth APIs and Bulk drugs in 2021-22.
The financial assistance by the centre is subject to a maximum limit of Rs.1000 crore per park
Pharma exports in 2021-22 sustain a positive growth despite global trade disruptions
The minister was speaking at the 7th International conference on Pharma and Medical Devices sector; chairs two roundtable conferences with the CEOs
The transaction as well as the open offer is expected to be completed by June this year.
In the April-September 2021 period, the FDI inflows continued to be buoyant at Rs 4,413 crore, growing at the rate of 53 per cent over the same period in 2020-21
Approvals accorded under Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical Key Starting Materials (KSMs)/ drug intermediates and Active Pharmaceutical Ingredients (APIs
A CRISIL study of 207 pharmaceutical companies that account for 55% of the Rs 3.2 lakh crore-a-year sector revenue indicates as much.
Subscribe To Our Newsletter & Stay Updated
